Drug
GDC-0084 clinical trials
Also written GDC-0084 and Paxalisib.
- studies test it
- 14
- open now
- 7
- in phase 3
- 1
- first study started
- 2012
Keep track of what changes. Save the GDC-0084 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 10
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 10
Kazia Therapeutics Limited (2) · Memorial Sloan Kettering Cancer Center (1) · Weill Medical College of Cornell University (1) · St. Jude Children's Research Hospital (1) · Genentech, Inc. (1) · Global Coalition for Adaptive Research (1) · Sovargen (1) · Lakshmi Nayak, MD (1)
Often tested with
Tested in the same studies.
Temozolomide (2) · Metformin (1) · Regorafenib (1) · Dianhydrogalactitol (1) · TSP-1 Activator VT1021 (1) · Troriluzole (1) · Pegargiminase (1) · AZD1390 (1)
Studies
Open first, then newest update. How each study uses GDC-0084 is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as Paxalisib
- Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)RecruitingPhase 1/2SovargenNCT07287202Written as SVG103
- Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLRecruitingPhase 2Lakshmi Nayak, MDNCT04906096Written as PAXALISIB
- Combination Therapy for the Treatment of Diffuse Midline GliomasRecruitingPhase 2University of California, San FranciscoNCT05009992Written as Paxalisib
- Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)RecruitingPhase 2Sabine Mueller, MD, PhDNCT07447076Written as Paxalisib
- 5G-PEARL: Paxalisib in Malignant Brain TumoursRecruitingPhase 1/2Institute of Cancer Research, United KingdomNCT07391215Written as Paxalisib
- Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerRecruitingPhase 1/2Australian & New Zealand Children's Haematology/Oncology GroupNCT06208657Written as Paxalisib
- Paxalisib With a High Fat, Low Carb Diet and Metformin for GlioblastomaCompletedPhase 2Weill Medical College of Cornell UniversityNCT05183204Written as Paxalisib
- GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain MetastasesTerminatedPhase 2Dana-Farber Cancer InstituteNCT03765983Written as GDC-0084
- GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal MetastasesActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT04192981Written as GDC-0084
- Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed GlioblastomaCompletedPhase 2Kazia Therapeutics LimitedNCT03522298Written as Paxalisib (GDC-0084)
- Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male SubjectsCompletedPhase 1Kazia Therapeutics LimitedNCT05012670Written as [14C]-Paxalisib Capsule
- Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline GliomasCompletedPhase 1St. Jude Children's Research HospitalNCT03696355Written as GDC-0084
- A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade GliomaCompletedPhase 1Genentech, Inc.NCT01547546Written as GDC-0084
Codes
What other systems call GDC-0084 · ClinicalTrials.gg INT001070
- MeSH (NLM) C000630586GDC-0084Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) P5DKZ70636PAXALISIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630586 | GDC-0084 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P5DKZ70636 | PAXALISIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.